Phosphodiesterase Type 5 Inhibitors: The Day After

European Urology

Volumn 51, Issue 1, 2007, Pages 75-89

  Hatzimouratidis, Konstantinos ^a   Hatzichristou, Dimitrios ^a  

^a PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

Author keywords

Endothelium; Erectile dysfunction; Phosphodiesterase inhibitors; Treatment outcome

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE PLUS ATORVASTATIN; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; EMLA; ISOSORBIDE DINITRATE; PAROXETINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TADALAFIL; TAMSULOSIN; VARDENAFIL;

CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; EJACULATION DISORDER; ENDOTHELIUM; ERECTILE DYSFUNCTION; FAT INTAKE; FOOD DRUG INTERACTION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOXIC LUNG VASOCONSTRICTION; ISCHEMIC OPTIC NEUROPATHY; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PEYRONIE DISEASE; PREMATURE EJACULATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PULMONARY HYPERTENSION; RECOMMENDED DRUG DOSE; REVIEW; SEXUAL INTERCOURSE; SIDE EFFECT; SINGLE DRUG DOSE; TACHYPHYLAXIS; TREATMENT RESPONSE; URETHRA DISEASE; VASCULAR DISEASE;

ANIMALS; CARBOLINES; HUMANS; IMIDAZOLES; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; SULFONES; TRIAZINES;

EID: 33751407982     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.07.020     Document Type: Review

References (98)

1. Feldman H.A., Goldstein I., Hatzichristou D.G., Krane R.J., and McKinlay J.B. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151 (1994) 54-61
2. Braun M., Wassmer G., Klotz T., Reifenrath B., Mathers M., and Engelmann U. Epidemiology of erectile dysfunction: results of the "Cologne Male Survey". Int J Impot Res 12 (2000) 305-311
3. Martin-Morales A., Sanchez-Cruz J.J., Saenz de Tejada I., Rodriguez-Vela L., Jimenez-Cruz J.F., and Burgos-Rodriguez R. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol 166 (2001) 569-574
4. Papaharitou S., Athanasiadis L., Nakopoulou E., et al. Erectile dysfunction and premature ejaculation are the most frequently self-reported sexual concerns: profiles of 9,536 men calling a helpline. Eur Urol 49 (2006) 557-563
5. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
6. Katz S.D., Balidemaj K., Homma S., Wu H., Wang J., and Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 36 (2000) 845-851
7. Halcox J.P., Nour K.R., Zalos G., et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 40 (2002) 1232-1240
8. Desouza C., Parulkar A., Lumpkin D., Akers D., and Fonseca V.A. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 25 (2002) 1336-1339
9. Kimura M., Higashi Y., Hara K., et al. PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers. Hypertension 41 (2003) 1106-1110
10. Vlachopoulos C., Tsekoura D., Alexopoulos N., Panagiotakos D., and Aznaouridis K. Stefanadis C. Type 5 phosphodiesterase inhibition by sildenafil abrogates acute smoking-induced endothelial dysfunction. Am J Hypertens 17 (2004) 1040-1044
11. Rosano G.M., Aversa A., Vitale C., Fabbri A., Fini M., and Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 47 (2005) 214-220
12. Caretta N., Palego P., Ferlin A., et al. Resumption of spontaneous erections in selected patients affected by erectile dysfunction and various degrees of carotid wall alteration: role of tadalafil. Eur Urol 48 (2005) 326-332
13. Gori T., Sicuro S., Dragoni S., Donati G., Forconi S., and Parker J.D. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. Circulation 111 (2005) 742-746
14. Foresta C., Caretta N., Lana A., Cabrelle A., Palu G., and Ferlin A. Circulating endothelial progenitor cells in subjects with erectile dysfunction. Int J Impot Res 17 (2005) 288-290
15. Foresta C, Ferlin A, De Toni L, et al. Circulating endothelial progenitor cells and endothelial function after chronic tadalafil treatment in subjects with erectile dysfunction. Int J Impot Res. In press.
16. Vlachopoulos C., Hirata K., and O'Rourke M.F. Effect of sildenafil on arterial stiffness and wave reflection. Vasc Med 8 (2003) 243-248
17. Hirata K., Adji A., Vlachopoulos C., and O'Rourke M.F. Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol 96 (2005) 1436-1440
18. Sairam K., Kulinskaya E., McNicholas T.A., Boustead G.B., and Hanbury D.C. Sildenafil influences lower urinary tract symptoms. BJU Int 90 (2002) 836-839
19. Atan A., Basar M.M., Tuncel A., Ferhat M., Agras K., and Tekdogan U. Comparison of efficacy of sildenafil-only, sildenafil plus topical EMLA cream, and topical EMLA-cream-only in treatment of premature ejaculation. Urology 67 (2006) 388-391
20. Chen J., Mabjeesh N.J., Matzkin H., and Greenstein A. Efficacy of sildenafil as adjuvant therapy to selective serotonin reuptake inhibitor in alleviating premature ejaculation. Urology 61 (2003) 197-200
21. Salonia A., Maga T., Colombo R., et al. A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. J Urol 168 (2002) 2486-2489
22. Wespes E., Amar E., Hatzichristou D., et al. EAU Guidelines on Erectile Dysfunction: an update. Eur Urol 49 (2006) 806-815
23. Hatzimouratidis K., and Hatzichristou D.G. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?. Drugs 65 (2005) 1621-1650
24. Padma-nathan H., Eardley I., Kloner R.A., Laties A.M., and Montorsi F. A 4-year update on the safety of sildenafil citrate (Viagra). Urology 60 (2002) 67-90
25. Montorsi F., Corbin J., and Phillips S. Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention. J Sex Med 1 (2004) 322-336
26. de Tejada I.S. Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat. Int J Impot Res 16 (2004) S40-S42
27. Basu A., and Ryder R.E. New treatment options for erectile dysfunction in patients with diabetes mellitus. Drugs 64 (2004) 2667-2688
28. Montorsi F., and McCullough A. Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: a systematic review of clinical data. J Sex Med 2 (2005) 658-667
29. Raina R., Lakin M.M., Agarwal A., et al. Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy. Urology 63 (2004) 960-966
30. Brausi M. High surgical volume, high quality, and low costs: a perfect combination is it always possible in patients who need radical prostatectomy?. Eur Urol 50 (2006) 17-19
31. Nandipati K.C., Raina R., Agarwal A., and Zippe C.D. Erectile dysfunction following radical retropubic prostatectomy: epidemiology, pathophysiology and pharmacological management. Drugs Aging 23 (2006) 101-117
32. Padma-Nathan H., Stecher V.J., Sweeney M., Orazem J., Tseng L.J., and Deriesthal H. Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. Urology 62 (2003) 400-403
33. Rosen R.C., Padma-Nathan H., Shabsigh R., Saikali K., Watkins V., and Pullman W. Determining the earliest time within 30 minutes to erectogenic effect after tadalafil 10 and 20 mg: a multicenter, randomized, double-blind, placebo-controlled, at-home study. J Sex Med 1 (2004) 193-200
34. Montorsi F., Padma-Nathan H., Buvat J., et al. Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebo-controlled trial. J Sex Med 1 (2004) 168-178
35. Hatzimouratidis K., Moysidis K., Bekos A., Tsimtsiou Z., Ioannidis E., and Hatzichristou D. Treatment strategy for "non-responders" to tadalafil and vardenafil: a real-life study. Eur Urol 50 (2006) 126-133
36. Porst H., Padma-Nathan H., Giuliano F., Anglin G., Varanese L., and Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 62 (2003) 121-125
37. Moncada I., Jara J., Subira D., Castano I., and Hernandez C. Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window. Eur Urol 46 (2004) 357-361
38. Porst H., Sharlip I.D., Hatzichristou D., et al. Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double-blind, placebo-controlled study. Eur Urol 50 (2006) 1086-1095
39. Hatzichristou D., Moysidis K., Apostolidis A., et al. Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 non-responders. Eur Urol 47 (2005) 518-523
40. Atiemo H.O., Szostak M.J., and Sklar G.N. Salvage of sildenafil failures referred from primary care physicians. J Urol 170 (2003) 2356-2358
41. Jiann B.P., Yu C.C., Su C.C., and Huang J.K. Rechallenge prior sildenafil nonresponders. Int J Impot Res 16 (2004) 64-68
42. Carson C., Giuliano F., Goldstein I., et al. The "effectiveness" scale-therapeutic outcome of pharmacologic therapies for ED: an international consensus panel report. Int J Impot Res 16 (2004) 207-213
43. Gruenwald I., Shenfeld O., Chen J., et al. Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil. Eur Urol 50 (2006) 134-140
44. Hatzichristou D.G. Sildenafil citrate: lessons learned from 3 years of clinical experience. Int J Impot Res 14 (2002) S43-S52
45. ®) in a broad population of European men. Eur Urol 45 (2004) 634-641
46. Jackson G., Kloner R.A., Costigan T.M., Warner M.R., and Emmick J.T. Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. J Sex Med 1 (2004) 161-167
47. Takimoto E., Champion H.C., Li M., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11 (2005) 214-222
48. Borlaug B.A., Melenovsky V., Marhin T., Fitzgerald P., and Kass D.A. Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation 112 (2005) 2642-2649
49. Kostis J.B., Jackson G., Rosen R., et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 96 (2005) 313-321
50. Fung M.M., Bettencourt R., and Barrett-Connor E. Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo Study. J Am Coll Cardiol 43 (2004) 1405-1411
51. McCormick J. Death of the personal doctor. Lancet 348 (1996) 667-668
52. Montorsi P., Ravagnani P.M., Galli S., et al. The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol 96 (2005) 19M-23M
53. Gazzaruso C., Giordanetti S., De Amici E., et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 110 (2004) 22-26
54. Montorsi F., Briganti A., Salonia A., et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 44 (2003) 360-365
55. Barrett-Connor E. Cardiovascular risk stratification and cardiovascular risk factors associated with erectile dysfunction: assessing cardiovascular risk in men with erectile dysfunction. Clin Cardiol 27 (2004) I8-I13
56. De Berardis G., Pellegrini F., Franciosi M., et al. Identifying patients with type 2 diabetes with a higher likelihood of erectile dysfunction: the role of the interaction between clinical and psychological factors. J Urol 169 (2003) 1422-1428
57. Franklin K., Goldberg R.J., Spencer F., et al. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch Intern Med 164 (2004) 1457-1463
58. Montorsi P., Ravagnani P.M., Galli S., et al. Association between erectile dysfunction and coronary artery disease: a case report study. J Sex Med 2 (2005) 575-582
59. Hatzichristou D., and Tsimtsiou Z. Prevention and management of cardiovascular disease and erectile dysfunction: toward a common patient-centered, care model. Am J Cardiol 96 (2005) 80M-84M
60. Kloner R.A., Jackson G., Emmick J.T., et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 172 (2004) 1935-1940
61. Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int 97 (2006) 34-38
62. Auerbach S.M., Gittelman M., Mazzu A., Cihon F., Sundaresan P., and White W.B. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology 64 (2004) 998-1003
63. Hatzichristou D. Phosphodiesterase 5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NAION): coincidence or causality?. J Sex Med 2 (2005) 751-758
64. Ghofrani H.A., Voswinckel R., Reichenberger F., et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 44 (2004) 1488-1496
65. Teixeira C.E., Priviero F.B., and Webb R.C. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. J Pharmacol Exp Ther 316 (2006) 654-661
66. Tsai B.M., Turrentine M.W., Sheridan B.C., et al. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression. Ann Thorac Surg 81 (2006) 272-278
67. Mulhall J.P., and Montorsi F. Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction. Eur Urol 49 (2006) 30-37
68. Eardley I., Mirone V., Montorsi F., et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int 96 (2005) 1323-1332
69. Montorsi F., Salonia A., Briganti A., et al. Vardenafil for the treatment of erectile dysfunction: a critical review of the literature based on personal clinical experience. Eur Urol 47 (2005) 612-621
70. Tsimtsiou Z., Hatzimouratidis K., Nakopoulou E., Kyrana E., Salpiggidis G., and Hatzichristou D. Predictors of physicians' involvement in addressing sexual health issues. J Sex Med 3 (2006) 583-588
71. Hatzichristou D., Rosen R.C., Broderick G., et al. Clinical evaluation and management strategy for sexual dysfunction in men and women. J Sex Med 1 (2004) 49-57
72. Athanasiadis L., Papaharitou S., Salpiggidis G., et al. Educating physicians to treat erectile dysfunction patients: development and evaluation of a course on communication and management strategies. J Sex Med 3 (2006) 47-55
73. Betancourt J.R., Green A.R., Carrillo J.E., and Park E.R. Cultural competence and health care disparities: key perspectives and trends. Health Aff (Millwood) 24 (2005) 499-505
74. McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med 1 (2004) 292-300
75. Mirone V., Costa P., Damber J.E., et al. An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries. Eur Urol 47 (2005) 846-854
76. Porst H., Giuliano F., Glina S., et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 50 (2006) 351-359
77. El-Galley R., Rutland H., Talic R., Keane T., and Clark H. Long-term efficacy of sildenafil and tachyphylaxis effect. J Urol 166 (2001) 927-931
78. Steers W.D. Tachyphylaxis and phosphodiesterase type 5 inhibitors. J Urol 168 (2002) 207
79. Behr-Roussel D., Gorny D., Mevel K., et al. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur Urol 47 (2005) 87-91
80. Musicki B., Champion H.C., Becker R.E., et al. In vivo analysis of chronic phosphodiesterase-5 inhibition with sildenafil in penile erectile tissues: no tachyphylaxis effect. J Urol 174 (2005) 1493-1496
81. Vernet D., Magee T., Qian A., Nolazco G., Rajfer J., and Gonzalez-Cadavid N. Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells. J Sex Med 3 (2006) 84-94
82. Schwartz E.J., Wong P., and Graydon R.J. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol 171 (2004) 771-774
83. Montorsi F., Briganti A., Salonia A., Rigatti P., and Burnett A.L. Can phosphodiesterase type 5 inhibitors cure erectile dysfunction?. Eur Urol 49 (2006) 979-986
84. Rosen R., Altwein J., Boyle P., et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol 44 (2003) 637-649
85. McVary K.T. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 47 (2005) 838-845
86. Uckert S., Oelke M., Stief C.G., Andersson K.E., Jonas U., and Hedlund P. Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 49 (2006) 740-745
87. Mulhall J.P., Guhring P., Parker M., and Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 3 (2006) 662-667
88. Abdel-Hamid I.A. Phosphodiesterase 5 inhibitors in rapid ejaculation: potential use and possible mechanisms of action. Drugs 64 (2004) 13-26
89. McMahon C.G., Stuckey B.G., Andersen M., et al. Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. J Sex Med 2 (2005) 368-375
90. Vogel R.A. Optimal vascular protection: a case for combination antihypertensive therapy. Prev Cardiol 9 (2006) 35-41
91. Tesfamariam B. The effects of HMG-CoA reductase inhibitors on endothelial function. Am J Cardiovasc Drugs 6 (2006) 115-120
92. Leibovitz E., Beniashvili M., Zimlichman R., Freiman A., Shargorodsky M., and Gavish D. Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. Am J Hypertens 16 (2003) 715-718
93. Kostis J.B., Rosen R.C., and Wilson A.C. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J Clin Pharmacol 34 (1994) 989-996
94. Saltzman E.A., Guay A.T., and Jacobson J. Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. J Urol 172 (2004) 255-258
95. Herrmann H.C., Levine L.A., Macaluso Jr. J., et al. Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. J Sex Med 3 (2006) 303-308
96. Mason R.P. A rationale for combination therapy in risk factor management: a mechanistic perspective. Am J Med 118 (2005) 54-61
97. McCullough A.R., Barada J.H., Fawzy A., Guay A.T., and Hatzichristou D. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology 60 (2002) 28-38
98. Dishy V., Harris P.A., Pierce R., et al. Sildenafil does not improve nitric oxide-mediated endothelium-dependent vascular responses in smokers. Br J Clin Pharmacol 57 (2004) 209-212